AngioDynamics, Inc. (ANGO) Receives Hold Rating from Canaccord Genuity

Canaccord Genuity restated their hold rating on shares of AngioDynamics, Inc. (NASDAQ:ANGO) in a report issued on Sunday. The brokerage currently has a $17.00 price target on the medical instruments supplier’s stock.

A number of other equities research analysts have also weighed in on the company. Zacks Investment Research raised AngioDynamics from a hold rating to a buy rating and set a $19.00 target price for the company in a research report on Tuesday, October 3rd. KeyCorp reaffirmed a hold rating on shares of AngioDynamics in a research report on Friday, September 29th. BidaskClub raised AngioDynamics from a sell rating to a hold rating in a research report on Saturday, August 19th. Barclays PLC decreased their target price on AngioDynamics from $17.00 to $16.00 and set an equal weight rating for the company in a research report on Wednesday, July 19th. Finally, Cantor Fitzgerald lifted their target price on AngioDynamics from $20.00 to $21.00 and gave the company an overweight rating in a research report on Tuesday, July 4th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $18.60.

Shares of AngioDynamics (NASDAQ:ANGO) traded down 1.204% during midday trading on Friday, reaching $16.825. The company had a trading volume of 72,344 shares. The firm’s 50 day moving average price is $17.34 and its 200-day moving average price is $16.38. The stock has a market capitalization of $617.73 million, a price-to-earnings ratio of 169.950 and a beta of 1.12. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period last year, the firm earned $0.17 earnings per share. Equities research analysts expect that AngioDynamics will post $0.66 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/09/angiodynamics-inc-ango-receives-hold-rating-from-canaccord-genuity.html.

In related news, CEO James C. Clemmer purchased 20,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were acquired at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Clemmer purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was bought at an average price of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders bought a total of 25,316 shares of company stock worth $396,806 over the last quarter. Company insiders own 1.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Broadfin Capital LLC grew its stake in AngioDynamics by 14.9% during the 2nd quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock worth $27,286,000 after buying an additional 217,800 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in AngioDynamics by 7.8% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,259 shares of the medical instruments supplier’s stock worth $458,000 after buying an additional 2,050 shares during the last quarter. California State Teachers Retirement System grew its stake in AngioDynamics by 21.6% during the 2nd quarter. California State Teachers Retirement System now owns 64,686 shares of the medical instruments supplier’s stock worth $1,049,000 after buying an additional 11,500 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in AngioDynamics by 32.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,321 shares of the medical instruments supplier’s stock worth $475,000 after buying an additional 7,130 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in AngioDynamics by 40.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 279,132 shares of the medical instruments supplier’s stock worth $4,525,000 after buying an additional 80,777 shares during the last quarter. Hedge funds and other institutional investors own 95.42% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply